Literature DB >> 35221864

Association of Blood Group Antigen CD59 with Disease.

Christof Weinstock1,2,3.   

Abstract

In 2014, the membrane-bound protein CD59 became a blood group antigen. CD59 has been known for decades as an inhibitor of the complement system, located on erythrocytes and on many other cell types. In paroxysmal nocturnal haemoglobinuria (PNH), a stem cell clone with acquired deficiency to express GPI-anchored molecules, including the complement inhibitor CD59, causes severe and life-threatening disease. The lack of CD59, which is the only membrane-bound inhibitor of the membrane attack complex, contributes a major part of the intravascular haemolysis observed in PNH patients. This crucial effect of CD59 in PNH disease prompted studies to investigate its role in other diseases. In this review, the role of CD59 in inflammation, rheumatic disease, and age-related macular degeneration is investigated. Further, the pivotal role of CD59 in PNH and congenital CD59 deficiency is reviewed.
Copyright © 2022 by S. Karger AG, Basel.

Entities:  

Keywords:  Blood group; CD59; Deficiency; Disease

Year:  2022        PMID: 35221864      PMCID: PMC8832213          DOI: 10.1159/000521174

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  112 in total

1.  Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack.

Authors:  O B Spiller; O Criado-García; S Rodríguez De Córdoba; B P Morgan
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

2.  Paroxysmal nocturnal hemoglobinuria. Enhanced stimulation of platelets by the terminal complement components is related to the lack of C8bp in the membrane.

Authors:  P Blaas; B Berger; S Weber; H H Peter; G M Hänsch
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

3.  Levels of expression of complement regulatory proteins CD46, CD55 and CD59 on resting and activated human peripheral blood leucocytes.

Authors:  Stephen E Christmas; Claudia T de la Mata Espinosa; Deborah Halliday; Cheryl A Buxton; Joanne A Cummerson; Peter M Johnson
Journal:  Immunology       Date:  2006-09-26       Impact factor: 7.397

4.  Neonatal-Onset Recurrent Guillain-Barré Syndrome-Like Disease: Clues for Inherited CD59 Deficiency.

Authors:  Didem Ardicli; Ekim Z Taskiran; Can Kosukcu; Cagri Temucin; Kader K Oguz; Goknur Haliloglu; Mehmet Alikasifoglu; Haluk Topaloglu
Journal:  Neuropediatrics       Date:  2017-08-11       Impact factor: 1.947

5.  Complement factor H variant increases the risk of age-related macular degeneration.

Authors:  Jonathan L Haines; Michael A Hauser; Silke Schmidt; William K Scott; Lana M Olson; Paul Gallins; Kylee L Spencer; Shu Ying Kwan; Maher Noureddine; John R Gilbert; Nathalie Schnetz-Boutaud; Anita Agarwal; Eric A Postel; Margaret A Pericak-Vance
Journal:  Science       Date:  2005-03-10       Impact factor: 47.728

6.  Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury.

Authors:  Joshua M Thurman; Brandon Renner; Kannan Kunchithapautham; Viviana P Ferreira; Michael K Pangburn; Zsolt Ablonczy; Stephen Tomlinson; V Michael Holers; Bärbel Rohrer
Journal:  J Biol Chem       Date:  2009-04-21       Impact factor: 5.157

7.  Evidence that the antigens of the Yt blood group system are located on human erythrocyte acetylcholinesterase.

Authors:  F A Spring; B Gardner; D J Anstee
Journal:  Blood       Date:  1992-10-15       Impact factor: 22.113

8.  Identification of a central role for complement in osteoarthritis.

Authors:  Qian Wang; Andrew L Rozelle; Christin M Lepus; Carla R Scanzello; Jason J Song; D Meegan Larsen; James F Crish; Gurkan Bebek; Susan Y Ritter; Tamsin M Lindstrom; Inyong Hwang; Heidi H Wong; Leonardo Punzi; Angelo Encarnacion; Mehrdad Shamloo; Stuart B Goodman; Tony Wyss-Coray; Steven R Goldring; Nirmal K Banda; Joshua M Thurman; Reuben Gobezie; Mary K Crow; V Michael Holers; David M Lee; William H Robinson
Journal:  Nat Med       Date:  2011-11-06       Impact factor: 53.440

9.  Molecular pathogenesis of human CD59 deficiency.

Authors:  Netanel Karbian; Yael Eshed-Eisenbach; Adi Tabib; Hila Hoizman; B Paul Morgan; Ora Schueler-Furman; Elior Peles; Dror Mevorach
Journal:  Neurol Genet       Date:  2018-10-26

10.  One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study.

Authors:  Hubert Schrezenmeier; Austin Kulasekararaj; Lindsay Mitchell; Flore Sicre de Fontbrune; Timothy Devos; Shinichiro Okamoto; Richard Wells; Scott T Rottinghaus; Peng Liu; Stephan Ortiz; Jong Wook Lee; Gérard Socié
Journal:  Ther Adv Hematol       Date:  2020-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.